The p1a/b basket trial is possibly the best of both worlds.
Validation (or not) in multiple indications, DCB's expensive P2 mBC trial didn't provide this (and was arguably a poor design as noted by several posters).
If JC is making his exit at arm's length via shaws - this is the best outcome for all holders. The risk of hostility is completely undermined and it makes more sense for a large partner to wait for CPACS validation in multiple indications before playing their hand.
Probably the best thing to happen for RAC since the surprising lack of toxicity observed in Sheba 2.0.
RAC - Charts & Price Action, page-19528
-
- There are more pages in this discussion • 2,511 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.65 |
Change
0.050(3.13%) |
Mkt cap ! $281.1M | |||
| Open | High | Low | Value | Volume |
| $1.63 | $1.70 | $1.52 | $318.0K | 193.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 496 | $1.65 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.70 | 5484 | 2 |
View Market Depth
| Last trade - 16.10pm 28/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |